Orion (ORNBV) CMD 2025 summary

Strategic direction and growth plans

• Achieved €1.5 billion net sales target ahead of schedule in 2024, with a 27% operating margin and €470 million profit.

• Strategy centers on innovation, geographic expansion, and portfolio diversification, focusing on oncology, pain, and value-added generics.

• Expanding commercial and R&D operations in Japan, US, UK, India, China, and APAC, with new R&D centers in the UK and US.

• All business divisions contribute, with ongoing investments in innovation, sustainability, and mastering the end-to-end value chain.

• Acquisitions and strategic partnerships are considered if they fit the growth plan.

Financial guidance and capital allocation

• Mid-term objectives (2024–2028): net sales CAGR of at least 8%, operating profit to grow faster than sales, equity ratio ≥50%, and return on equity >25%.

• Dividend policy targets annual increases with a payout ratio of 50–100%.

• R&D spend historically 10–12% of net sales, with CapEx expected at 4–5% in coming years.

• Revenue targeted to grow from €1.5B to €2B by 2028, with increased R&D and CapEx investments.

• Capital allocation prioritizes internal R&D, dividends, manufacturing, in-licensing, and targeted M&A, with up to €2 billion M&A capacity.

Business division updates and growth drivers

• Innovative medicines: Nubeqa (darolutamide) and opevesostat drive growth, with label expansions and robust pipeline including ODM-105 (insomnia) and ODM-212 (oncology/TEAD inhibitor).

• Branded products: Easyhaler respiratory and Parkinson’s treatments are central, with Easyhaler sales targeted to exceed €300M; expanding women’s health and leveraging omnichannel engagement.

• Generics and consumer health: Portfolio shift toward complex generics, new digital sales channels, and expansion in Europe’s Big5, Scandinavia, and Poland.

• Animal health: Integrated operations post-acquisitions, focus on innovation, sustainable antibiotics, and new launches in companion and livestock segments.

• Exploring targeted M&A to expand product portfolio and commercial presence.